Alamar Biosciences (NASDAQ:ALMR) Announces Earnings Results

Alamar Biosciences (NASDAQ:ALMR) announced its earnings results on Friday. The company reported ($1.74) earnings per share for the quarter, Zacks reports. The firm had revenue of $26.04 million for the quarter.

Alamar Biosciences Stock Performance

Alamar Biosciences stock traded up $0.34 during mid-day trading on Friday, reaching $24.00. 218,914 shares of the company were exchanged, compared to its average volume of 352,978. Alamar Biosciences has a 12-month low of $21.50 and a 12-month high of $27.20.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Alamar Biosciences to a “hold” rating in a research note on Saturday, April 25th.

Insiders Place Their Bets

In related news, Director Nicholas Naclerio acquired 235,294 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The shares were bought at an average price of $17.00 per share, with a total value of $3,999,998.00. Following the completion of the transaction, the director directly owned 507,076 shares in the company, valued at $8,620,292. This trade represents a 86.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Innovation Fund Gp Illumina II bought 235,294 shares of the business’s stock in a transaction on Monday, April 20th. The stock was bought at an average price of $17.00 per share, for a total transaction of $3,999,998.00. Following the purchase, the insider directly owned 507,076 shares of the company’s stock, valued at $8,620,292. The trade was a 86.57% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Alamar Biosciences Company Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.